Figure 5.
Complete remission from active AML after mLST infusion. MRI images of AML invading bone before (A) and after (B) mLST infusion. (C) Relapsed AML cells (CD33+ blasts; IHC). Hematoxylin and eosin; original magnification ×400. Cells were surrounded by a dense infiltrate of CD3+ T cells. IHC; original magnification ×10. Changes in frequency of circulating mLSTs after infusion, as measured by IFN-γ ELISpot (D) and polyclonality of circulating WT1-specific T cells, as estimated by ICS (E) performed on fresh PBMCs at the 6-month time point. (F) Change in the frequency of mLST-derived TCR clones represented as fold change from baseline in the repertoire frequency.

Complete remission from active AML after mLST infusion. MRI images of AML invading bone before (A) and after (B) mLST infusion. (C) Relapsed AML cells (CD33+ blasts; IHC). Hematoxylin and eosin; original magnification ×400. Cells were surrounded by a dense infiltrate of CD3+ T cells. IHC; original magnification ×10. Changes in frequency of circulating mLSTs after infusion, as measured by IFN-γ ELISpot (D) and polyclonality of circulating WT1-specific T cells, as estimated by ICS (E) performed on fresh PBMCs at the 6-month time point. (F) Change in the frequency of mLST-derived TCR clones represented as fold change from baseline in the repertoire frequency.

Close Modal

or Create an Account

Close Modal
Close Modal